Oral Session 2-11C Novel therapies for ALL

[OS2-11C-2] Outcome of Asian R/R ALL patients receiving inotuzumab ozogamicin or standard care in INO-VATE trial

Masayuki Hino¹, Toshiki Uchida², Yasushi Onishi³, Chul Won Jung⁴, Yeow Tee Goh⁵, Kiyoshi Ando⁶, Ming Chung Wang⁷, Chiho Ono⁸, Miyako Matsumizu⁸, M. Luisa Paccagnella⁹, Barbara Sleight⁹, Erik Vandendries¹⁰, Yosuke Fujii⁸, Naohito Fujishima¹¹ (1.Hematology, Osaka City University, Osaka, Japan, 2.Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan, 3.Tohoku University Hospital, Sendai, Japan, 4.Samsung Medical Center, Seoul, South Korea, 5.Singapore General Hospital, Bukit Merah, Singapore, 6.Tokai University Hospital, Isehara, Japan, 7.Chang Gung Medical Foundation, Taipei, Taiwan, 8.Pfizer Japan Inc, 9.Pfizer Inc, Groton, CT, USA, 10.Pfizer Inc, Cambridge, MA, USA, 11.Akita University, Akita, Japan)